Monte Rosa said it expects three programs, MRT-6160, MRT-8102 and MRT-2359, to initiate Phase 2 trials in 2026. The company said it anticipates additional INDs for its wholly owned pipeline over the next two years, including an IND submission for a CCNE1 molecular glue degrader in 2026. Monte Rosa said it received about USD 350 million in collaboration payments over the last three years and sees potential for more than USD 400 million over the next 24 months. It said a Novartis license for VAV1-directed molecular glue degraders, including MRT-6160, included a USD 150 million upfront payment and up to USD 2.1 billion in milestones. Monte Rosa also said a separate Novartis collaboration had a total deal value of up to USD 5.7 billion, and a Roche collaboration included a USD 50 million upfront payment and more than USD 2 billion in potential milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.